USPTO Patent Application for Self-Emulsifying Drug Delivery Systems

ChangeBridge: Patent Apps - Pharma (A61K)

Published September 20th, 2024

Detected March 26th, 2026

Summary

The USPTO has published a patent application from Fertin Pharma A/S for a dosage form utilizing self-emulsifying drug delivery systems (SEDDS) for cannabinoids. The application details specific formulations including surfactants with PEG moieties and isolated or synthetic cannabinoids.

View original document View source feed page

What changed

This document is a USPTO patent application (US20260083757A1) filed by Fertin Pharma A/S, detailing a dosage form for delivering cannabinoids. The formulation incorporates self-emulsifying drug delivery systems (SEDDS) with a significant percentage of polyethylene glycol (PEG) surfactants and at least 10% by weight of isolated or synthetic cannabinoids.

As this is a patent application, it does not impose immediate regulatory obligations. However, it signifies potential future developments in cannabinoid drug delivery systems. Companies operating in the pharmaceutical and cannabinoid sectors should be aware of this application as it may impact future product development and intellectual property landscapes. The filing date was September 20, 2024, with a publication date of March 26, 2026.

Source document (simplified)

← USPTO Patent Applications

Dosage Forms For Delivery Of Self-Emulsifying Drug Delivery Systems

Application US20260083757A1 Kind: A1 Mar 26, 2026

Assignee

Fertin Pharma A/S

Inventors

Sanne Skov Jensen, Gitte Nykjær Nikolajsen, Benjamin Bugge Wahlqvist

Abstract

A dosage form for delivery of cannabinoids includes a formulation including: one or more self-emulsifying drug delivery systems (SEDDS) including one or more surfactants having a chemical structure that includes a polyethylene glycol (PEG) moiety in an amount of at least 30% by weight of the one or more SEDDS; and one or more cannabinoids including one or more isolated or synthetic cannabinoids in an amount of at least 10% by weight of the formulation.